ArticleInternational journal of women's health2025
Malignant Peritoneal Cytology Predicts Poor Prognosis and Differential Adjuvant Therapy Benefit in Endometrioid Endometrial Carcinoma: A SEER-Based Propensity Score-Matched Analysis.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of malignant peritoneal cytology (PC) in endometrioid endometrial carcinoma (EC) and its clinical implications for adjuvant therapy selection remain controversial. Methods: This retrospective cohort study analyzed 9631 endometrioid EC patients from Surveillance, Epidemiology, and End Results (SEER) Program data (2010-2017). Prognostic determinants of overall survival (OS) were identified through Cox regression. Propensity score matching (PSM) generated balanced cohorts: 826 malignant PC, 148 atypical/suspicious PC, and 974 negative PC cases. Survival distributions were compared using Kaplan-Meier analysis. Results: Univariable analysis identified significant OS associations with age, histopathological grade, tumor stage, and PC status (all p < 0.05). Multivariable analysis confirmed malignant PC as an independent prognostic factor. Post-PSM: Malignant PC subgroup showed significantly reduced OS vs others (p < 0.001). Stage-specific effects in malignant PC subgroup: Radiation improved OS only in regional disease (p = 0.016). Systemic therapy reduced OS in all-stage malignant PC (p = 0.022). Atypical/suspicious PC subgroup: No survival benefit from radiation (p = 0.71) or systemic therapy (p = 0.38). Conclusion: Malignant PC independently predicts poor prognosis in endometrioid EC but requires cautious interpretation in therapeutic decision-making due to its differential adjuvant therapy effects. PC status alone cannot guide risk stratification; treatment decisions should integrate stage-specific efficacy data. Prospective validation is imperative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.